SECURITIES INTELLIGENCE AND ISSUER DEFENSE
Anomaly Signal Co. owns and operates:
BioAlpha Terminal: Forensic signal detection across 975 biotech and pharmaceutical companies. Twenty-two independent signals. Timestamped evidence packages for securities litigation, investment signals, and equity research.
SignalForce: Defense infrastructure for public companies. Eight patents pending. Zero competitors. Addresses the single largest unprotected vulnerability affecting issuer stock price.
Timestamped. Quantitative. Admissible.
BioAlpha Terminal operates on a simple principle. In biotech markets, the data moves before the news. The system monitors 975 companies daily through twenty-two independent quantitative signals, documenting exactly when trading behavior, insider activity, and market microstructure shifted relative to public disclosure. Indication-specific probability of success models provide clinical context: oncology Phase 3 base rate of 3.4%, vaccines 33.4%, CNS 8%. Insiders trading against these odds is the story the data tells.
Every reading is timestamped, sourced, and structured for evidentiary use. The output is a forensic record of what moved, when it moved, and how far ahead of the announcement it moved.
The litigation product is a timestamped forensic record. It shows when volume deviated from baseline, when insiders transacted, when the options market re-priced, and when the public was finally informed. The time gaps between these events are the core of a securities fraud case. BioAlpha packages them with source attribution, confidence scoring, and statistical context for counsel review.
The timing data also generates investment signals. When signals converge ahead of a catalyst, the system scores the setup. 80% accuracy. 4.86 Sharpe ratio. Walk-forward validated on 3,972 historical events.
For biotech and biopharma employees with equity in their company. The reports show where your company sits on the catalyst timeline, what insider and microstructure signals indicate, and what historical base rates predict for your therapeutic area.
975 companies. 22 signals. Every trading day.
The vulnerability no one is measuring
The market does not reward what you know. It rewards what you see first.